Available Technologies
# of Displayed Technologies: 10 / 16
Applied Category Filter (Click To Remove): Therapeutics
Addressing the Challenges in HCC Treatment with Innovative Technology
TS-062690 — Novel niclosamide analogues with improved bioavailability and mitigated dose-limiting toxicities.
Hepatocellular carcinoma (HCC) poses a significant global health challenge, being a predominant form of liver cancer with high mortality rates. The disease exhibits sexual dimorphism, disproportionately affecting males.
The Need
Despite the crucial role of androgen receptors (AR) in HCC progress…
- College: College of Pharmacy
- Inventors: Coss, Christopher; Cheng, Jeffrey; Cheng, Xiaolin; Kulp, Samuel; Li, Tom; Montgomery, Emma; Xing, Enming
- Licensing Officer: Schultz, Teri
Immune Based Neuroprotective & Neuroregenerative Therapies
TS-062688 — Conditioned neutrophils and cell therapy vectors for nerve regeneration
The Need
Neurological disorders arising from central nervous system (CNS) injuries and diseases pose significant challenges to quality of life. The limited capacity of CNS neurons to regenerate and the lack of effective therapies for conditions like glaucoma, optic nerve injury, and spinal cord inj…
- College: College of Medicine (COM)
- Inventors: Segal, Benjamin; Jerome, Andrew; Liu, Tom; Sas, Andrew
- Licensing Officer: Bhatti, Hamid
Transducin β-like protein 1 X-Linked Selective Degraders as Anti-cancer Therapeutics
TS-062685 — Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum and prostate cancers.
The Need
Current cancer treatments mainly rely on chemotherapy, radiation, surgery and bon…
- College: College of Pharmacy
- Inventors: Cheng, Xiaolin; Alinari, Lapo; Li, Pui-Kai "Tom"; Yang, Rui
- Licensing Officer: Willson, Christopher
E-Cadherin-based Oncolytic Viral Cancer for Glioblastoma
TS-062682 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year.
The Need
Oncolytic viruses (OVs) are a prom…
- College: College of Medicine (COM)
- Inventors: Yu, Jianhua; Caligiuri, Michael; Xu, Bo
- Licensing Officer: Taysavang, Panya
An innovative platform to enhance the efficacy of oncolytic virotherapy for cancer treatment through E-cadherin
TS-062679 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year.
The Need
Oncolytic viruses (OVs) are a prom…
- College: College of Medicine (COM)
- Inventors: Yu, Jianhua; Caligiuri, Michael; Xu, Bo
- Licensing Officer: Taysavang, Panya
Dual Androgen Receptor/AKR1C3 Inhibitors for Prostate Cancer
TS-062605 — The Need:
Castration-resistant prostate cancer (CRPC) poses a significant challenge in oncology, with existing therapies often leading to resistance and disease progression. Key drivers of resistance include the androgen receptor (AR) and aldo-keto reductase family 1 member C3 (AKR1C3). Novel treat…
- College: College of Pharmacy
- Inventors: Li, Pui-Kai "Tom"; Cheng, Xiaolin; Kong, Xiaotian; Xing, Enming
- Licensing Officer: Schworer, Adam
An Orally Active, Selective Inhibitor of CD4+ T-Cell Activation That Blunts Left-Ventricular Remodeling and Improves Cardiac Function during Chronic Heart Failure
TS-057777 —
A novel orally-active drug molecule that can inhibit pathological CD4+ T-cells at clinically translatable doses and, blunts progressive cardiac dysfunction and left-ventricular (LV) remodeling during Heart Failure (HF).
HF afflicts ~6.5 million adults in US with 50% mortality in first 5 years. It has an estimated market size of $4.2B USD in US alone with a forecasted CAGR of 23% from 2018-2028. Current HF treatments are mostly aimed at alleviating symptoms rather than treatment, resulting in progressive cardiac d…
- College: College of Medicine (COM)
- Inventors: Bansal, Shyam; Gumina, Richard
- Licensing Officer: He, Panqing
Mini-PCDH15 for treatment of deafness
TS-050433 — A gene therapy solution for Usher Syndrome Type 1F.
Mutations in PCDH15 cause Usher 1F, a recessive syndrome characterized by profound congenital deafness and absence of vestibular function, and progressive blindness beginning in the second decade. Because patients who lack hearing and balance rely on vision for communication and mobility, the late…
- College: College of Arts & Sciences
- Inventors: Sotomayor, Marcos
- Licensing Officer: Willson, Christopher
Multi-Functional Drug Delivery Nanodevice for Precision Medicine
TS-041485 — A functionalized DNA nanostructure made through a scaffolded DNA origami molecular self-assembly process to deliver clinically significant concentrations of therapeutics.
This novel therapeutic approach leverages structural nanotechnology to create a DNA nanostructure that acts as a customizable delivery vehicle for therapeutic molecules. The technology allows for a highly tunable and customizable multi-functional drug delivery platform that incorporates interchang…
- College: College of Engineering (COE)
- Inventors: Castro, Carlos; Byrd, John; Halley, Patrick; Lucas, Christopher
- Licensing Officer: He, Panqing
Six Degrees-of-Freedom Quality Assurance Phantom for Radiation Therapy Linear Accelerators
TS-037968 — The medical physics group in the Department of Radiation Oncology has devised a 6DoF phantom that is the first of its kind to fully integrate multiple routine QA tests specifically for a six degrees-of-freedom linac table.
6DoF treatment tables allow for 2 additional degrees (pitch and roll) compared to traditional 4DoF (vertical, lateral, longitudinal, and yaw) when correcting for patient setup during image-guidance prior to treatment delivery. These tables allow for more accurate patient treatments and could poten…
- College: OSU Wexner Medical Center
- Inventors: Woods, Kyle; Ayan, Ahmet; Gupta, Nilendu; Woollard, Jeffrey
- Licensing Officer: Schworer, Adam
